Small panels covering classic driver genes tend to be cost-effective and an increasing trend of applying small panel in early-stage LADC has been observed.
← all excerpts
First-line treatment selection with organoids of an <i>EGFR</i>m + <i>TP53</i>m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up.
1
—
—